WallStSmart

Axogen Inc (AXGN)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 8814% more annual revenue ($20.07B vs $225.21M). BSX leads profitability with a 14.4% profit margin vs -7.0%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

AXGN

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 5.3
Piotroski: 3/9Altman Z: 0.00

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXGN.

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXGN1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.3%8/10

Revenue surging 21.3% year-over-year

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

Areas to Watch

AXGN4 concerns · Avg: 3.5/10
Price/BookValuation
12.2x4/10

Trading at 12.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AXGN

The strongest argument for AXGN centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bear Case : AXGN

The primary concerns for AXGN are Price/Book, EPS Growth, Market Cap.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Key Dynamics to Monitor

AXGN carries more volatility with a beta of 1.02 — expect wider price swings.

AXGN is growing revenue faster at 21.3% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 31/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?